Based on this, the identification of NRF2 inhibitors is rapidly emerging as a promising anticancer strategy in solid and hematologic cancers characterized by persistent NRF2 activation. The gene discussed is NFE2L2; the disease is hematopoietic and lymphoid cell neoplasm.